Logo

Still Awaiting Approval by Chinese Agencies, BGI-Shenzhen Extends Offer for Complete Genomics

Feb 08, 2013 | staff reporter

NEW YORK (GenomeWeb News) – BGI-Shenzhen said late on Wednesday that it has again extended its cash tender offer for Complete Genomics.

The offer is now set to expire midnight EST on Feb. 22. The extension is to allow China's Ministry of Commerce time to approve the deal and China's State Administration of Foreign Exchange to register the transaction, BGI said. It also noted the upcoming Chinese New Year holiday in China, which is set to begin Feb. 9 and end Feb. 15.

The $118 million deal had been set to expire midnight on Feb. 6.

The depositary for the offer has indicated that as of the close of business on Wednesday, about 30,967,711 shares, or 87 percent, of Complete Genomics' common stock have been tendered and not withdrawn.

Filed under

Clinical Sequencing
Sequencing
Business News
tender offer
mergers & acquisitions
MGI Tech
BGI
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.